ADC Therapeutics Presents Promising ZYNLONTA Data at ASH; LOTIS-5 Shows Mixed Safety
ADC Therapeutics announced new and updated data from its ZYNLONTA clinical program to be presented at the 68th ASH Annual Meeting. Key data includes positive results from the LOTIS-7 Phase 1b trial combining ZYNLONTA with glofitamab, showing an 88.7% ORR and 75.3% CR in relapsed/refractory DLBCL. Additionally, updated data from a Phase 2 investigator-initiated trial in marginal zone lymphoma demonstrated a 93% ORR and 74.4% CRR. The company also presented full results from the Phase 3 LOTIS-5 study, which met its primary PFS endpoint but showed a higher rate of Grade 5 adverse events in the ZYNLONTA arm. Preliminary financial estimates for Q3 2026 were also provided.
Key Highlights
- LOTIS-7 Phase 1b trial: ZYNLONTA + glofitamab showed 88.7% ORR and 75.3% CR in r/r DLBCL patients.
- LOTIS-7: 50% of patients achieving CR had undetectable MRD as early as Cycle 2, Day 1.
- Phase 2 IIT for ZYNLONTA in r/r marginal zone lymphoma showed 93% ORR and 74.4% CRR.
- LOTIS-5 Phase 3 trial: ZYNLONTA + rituximab showed median PFS of 6.14 months vs 4.73 months for R-GemOx.
- LOTIS-5: Grade 5 TEAEs were higher in the ZYNLONTA + rituximab arm (13.2% vs 4.6%).
- ZYNLONTA in r/r MCL (COLUMN trial): Loncastuximab consolidation deepened CR rate from 46.9% to 71.4%.
- ZYNLONTA in r/r WM (WM-NET1 trial): High ORR of 90% and VGPR/CR of 60% in heavily pre-treated patients.
Price Impact
More from ADCT
ADC Therapeutics Q2 Net Loss Narrows to $16.6M; Product Revenue Up
ADC Therapeutics Q2 Net Loss $16.6M; FDA Raises Concerns on ZYNLONTA LOTIS-5
ADC Therapeutics Grants $2.9M Cash & 1.09M RSU Retention Awards to Executives